Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
10.3904/kjim.2015.30.1.32
- Author:
Hyo Jin KIM
1
;
Ju Yeon CHO
;
Yu Jin KIM
;
Geum Youn GWAK
;
Yong Han PAIK
;
Moon Seok CHOI
;
Kwang Cheol KOH
;
Seung Woon PAIK
;
Byung Chul YOO
;
Joon Hyeok LEE
Author Information
1. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. liverjhlee@skku.edu
- Publication Type:Original Article
- Keywords:
Tenofovir;
Hepatitis B, chronic;
Treatment failure;
Resistance
- MeSH:
Adenine/adverse effects/*analogs & derivatives/therapeutic use;
Adult;
Aged;
Alanine Transaminase/blood;
Antiviral Agents/adverse effects/*therapeutic use;
Biological Markers/blood;
Creatinine/blood;
DNA, Viral/blood;
Drug Resistance, Viral/genetics;
Drug Substitution;
Female;
Genotype;
Hepatitis B e Antigens/blood;
Hepatitis B virus/*drug effects/genetics/immunology/pathogenicity;
Hepatitis B, Chronic/blood/diagnosis/*drug therapy;
Humans;
Kaplan-Meier Estimate;
Male;
Middle Aged;
Mutation;
Phosphorous Acids/adverse effects/*therapeutic use;
Phosphorus/blood;
Retrospective Studies;
Time Factors;
Treatment Failure;
Viral Load;
Young Adult
- From:The Korean Journal of Internal Medicine
2015;30(1):32-41
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: The efficacy of tenofovir disoproxil fumarate (TDF) for the treatment of chronic hepatitis B (CHB) patients following prior treatment failure with multiple nucleos(t)ide analogues (NAs) is not well defined, especially in Asian populations. In this study we investigated the efficacy and safety of TDF rescue therapy in CHB patients after multiple NA treatment failure. METHODS: The study retrospectively analyzed 52 CHB patients who experienced failure with two or more NAs and who were switched to regimens containing TDF. The efficacy and safety assessments included hepatitis B virus (HBV) DNA undetectability, hepatitis B envelop antigen (HBeAg) seroclearance, alanine transaminase (ALT) normalization and changes in serum creatinine and phosphorus levels. RESULTS: The mean HBV DNA level at baseline was 5.4 +/- 1.76 log10 IU/mL. At a median duration of 34.5 months of TDF treatment, the cumulative probabilities of achieving complete virological response (CVR) were 25.0%, 51.8%, 74.2%, and 96.7% at 6, 12, 24, and 48 months, respectively. HBeAg seroclearance occurred in seven of 48 patients (14.6%). ALT levels were normalized in 27 of 31 patients (87.1%) with elevated ALT at baseline. Lower levels of HBV DNA at baseline were significantly associated with increased CVR rates (p < 0.001). However, CVR rates did not differ between TDF monotherapy or combination therapy with other NAs, and were not affected by mutations associated with resistance to NAs. No significant adverse events were observed. CONCLUSIONS: TDF is an efficient and safe rescue therapy for CHB patients after treatment failure with multiple NAs.
